Description: Cagrilintide is a long‑acting, injectable amylin analogue that acts on amylin receptors to slow gastric emptying, reduce appetite, and promote weight loss in preclinical and clinical studies. It is being investigated for metabolic and obesity‑related indications, often in combination with GLP‑1 receptor agonists.
Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. For in vitro testing and laboratory experimentation by qualified professionals. Bodily introduction into humans or animals is forbidden. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic
